[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou Suncadia Biopharmaceuticals Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":526},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,43,65,88,111,131,150,169,190,210,230,251,270,290,310,331,350,370,389,410,429,449,470,488,507],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054025","phase-2-clinical-study-on-the-treatment-of-mibc-patients-with-shr-a2102-injection-combined-with-adebrelimab-shr-1316-100054025",false,"NCT06879145","Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","A Randomized, Open, Multicenter Phase II\u002FIII Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)","Inclusion Criteria:\n\n\\- 1.18-80 years old, gender not limited. 2.The patient voluntarily joined this study and signed informed consent 3.ECOG score is 0 or 1 4.Expected survival period ≥ 2 years. 5.Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer 6.There are assessable lesions that meet the RECIST 1.1 criteria 7. Enough organ function\n\nExclusion Criteria:\n\n1. Received systemic anti-tumor therapy 4 weeks before starting the study treatment\n2. The toxicity and\u002For complications of previous anti-tumor treatments have not recovered to NCI-CTCAE ≤ 1 level\n3. Subjects known or suspected to have interstitial pneumonia\n4. Individuals with any active, known or suspected autoimmune diseases\n5. There are clinical symptoms or diseases of the heart that have not been well controlled\n6. Diagnosed with any other malignant tumor\n7. Subjects who have experienced severe infections within 28 days prior to their first medication use\n8. History of immunodeficiency\n9. Use of attenuated live vaccine within 28 days prior to the first study medication\n10. Have undergone major surgery within 28 days prior to the first administration of medication","ALL","18 Years","80 Years",{"count":21,"type":22},840,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).",[29],"Muscular Invasive Bladder Cancer (MIBC)","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-04-25",{"date":38,"type":22},"2031-12",{"name":40,"class":41},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100587533","phase-3-a-phase-3-clinical-study-of-shr-a1912-combined-with-r-gemox-versus-r-gemox-in-diffuse-large-b-cell-lymphoma-100587533","NCT06929624","A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).\n2. Have received ≥1 line of systemic antitumor therapy.\n3. At least one bi-dimensionally measurable lesion.\n4. Expected survival of at least 3 months.\n5. Age ≥18 years old and under 80 years old.\n6. The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Central nervous system lymphoma involvement.\n2. Primary mediastinal (thymus) large B-cell lymphoma.\n3. Patients who have only one prior line therapy and are candidates for stem cell transplantation.\n4. A history of immunodeficiency.\n5. A history of severe cardiovascular disease.\n6. A history of other malignancies within 5 years prior to administration of the first dose.",{"count":51,"type":22},280,[26],"This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.",[55],"Diffuse Large B-cell Lymphoma","2026-06-29",{"date":58,"type":34},"2026-07-01",{"date":60,"type":34},"2025-04-24",{"date":62,"type":22},"2028-01",{"name":40,"class":41},2,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":64},"100597494","phase-1-a-trial-of-shr-a2102-with-adebrelimab-with-or-without-other-anti-tumor-therapies-in-recurrentmetastatichead-and-neck-squamous-cell-carcinoma-cancer-100597494","NCT07059221","A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent\u002FMetastaticHead and Neck Squamous Cell Carcinoma Cancer","A Multicenter, Open-label Phase Ib\u002FII Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements.\n2. Subject with advanced or distant metastatic squamous cell carcinoma of the head and neck confirmed by histology or cytology.\n3. At least one measurable lesion according to RECIST v1.1 criteria.\n4. The ECOG score is 0 or 1.\n5. Expected survival ≥12 weeks.\n6. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.\n\nExclusion Criteria:\n\n\\-\n\n1\\. Subjects will not be screened if they meet any of the following conditions:\n\n1. Primary tumor located in the nasopharynx, salivary glands, sinuses, skin, or squamous cell carcinoma of unknown primary origin;\n2. Locally advanced patients who are candidates for curative surgery or local therapy and have the intention to undergo such treatment;\n\n2\\. Known hypersensitivity to the investigational drug or any of its excipients, or a history of severe allergic reactions to other monoclonal antibodies.\n\n3\\. Prior treatments or medications before the first dose of the study drug:\n\n1. Use of any investigational drug within 4 weeks before the first dose;\n2. Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) study or follow-up in an interventional study; 4. Active autoimmune disease or a history of autoimmune disorders. 5. Residual toxicity from prior anticancer therapy not resolved to ≤Grade 1 (CTCAE v5.0) (except for non-safety risks, such as alopecia) or not meeting the inclusion\u002Fexclusion criteria.\n\n6\\. Uncontrolled or symptomatic active CNS metastases. 7. Symptomatic visceral metastases with imminent life-threatening complications .\n\n8\\. Severe bone damage caused by tumor bone metastasis, including severe bone pain that is poorly controlled; pathological fractures in important areas that occurred within 6 months before the first medication or are expected to occur very soon; and spinal cord compression.\n\n9\\. Known or suspected interstitial lung disease (ILD) or severe pulmonary conditions.\n\n10\\. Other active malignancies within 3 years before study entry. 11. Have a history of immunodeficiency, including a positive HIV test result, or suffer from other acquired or congenital immune deficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation.\n\n12\\. Clinically significant cardiovascular disease. 13. Active or chronic infections of clinical significance. 14. Pregnancy or lactation. 15. Other factors that, in the investigator's judgment, may lead to premature study discontinuation.","75 Years",{"count":74,"type":22},210,[76,25],"PHASE1","The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102\u002FSHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma.\n\nTo explore the reasonable dosage of SHR-A2102\u002FSHR-9839（sc） for Subjects with Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[79],"Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma","2026-06-28",{"date":82,"type":34},"2026-06-30",{"date":84,"type":34},"2025-07-11",{"date":86,"type":22},"2029-03",{"name":40,"class":41},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100645240","phase-2-a-trial-of-shr-8068-combined-with-adebrelimab-and-apatinib-in-perioperative-treatment-of-resectable-hepatocellular-carcinoma-100645240","NCT07682272","A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma","A Randomized, Open-label, Multicenter Phase II Study of SHR-8068 Combined With Adebrelimab and Apatinib for Perioperative Treatment in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk","Inclusion Criteria:\n\n1. Subjects who voluntarily participate in this study and sign the informed consent form.\n2. Age from 18 to 70, male or female.\n3. Histopathologically\u002Fcytologically confirmed or clinically diagnosed with hepatocellular carcinoma (HCC).\n4. At least one measurable lesion based on RECIST v1.1.\n5. No prior systemic antitumor therapy for HCC.\n6. ECOG Performance Status (PS) score of 0-1.\n7. Child-Pugh liver function class A.\n8. Expected survival at least 3 months.\n9. Adequate organ function.\n10. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.\n\nExclusion Criteria:\n\n1. Known intrahepatic cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma.\n2. Other malignancies within the past 5 years or concurrent malignancy.\n3. Known history of severe hypersensitivity reaction to any monoclonal antibody.\n4. Previous or current central nervous system metastases.\n5. Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage.\n6. Hypertension that cannot be well controlled with antihypertensive medication.\n7. Poorly controlled cardiac symptoms or heart disease.\n8. Known hereditary or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency.\n9. Arterial thrombotic or embolic events within 6 months before enrollment.\n10. Any other condition that, in the investigator's judgment, may affect the study results or lead to premature termination of the study.","70 Years",{"count":97,"type":22},120,[25],"This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.",[101],"Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk","NOT_YET_RECRUITING","2026-06-26",{"date":105,"type":34},"2026-07-02",{"date":107,"type":22},"2026-07",{"date":109,"type":22},"2029-07",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":118,"minAge":18,"maxAge":72,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100645166","phase-3-a-study-of-trastuzumab-rezetecan-in-combination-with-adebrelimab-versus-investigators-choice-of-therapy-in-subjects-with-residual-triple-negative-breast-cancer-100645166","NCT07679360","A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy","Inclusion Criteria:\n\n1. Pathologically confirmed invasive triple negative breast cancer.\n2. Pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy.\n3. Previous neoadjuvant therapy must meet the requirements of the protocol.\n4. Has received radical surgery for breast cancer.\n5. ECOG PS 0\\~1.\n6. Adequate organ functions.\n7. Women of childbearing potential must be willing to use highly effective form of contraception.\n\nExclusion Criteria:\n\n1. Stage IV metastatic breast cancer.\n2. Previous invasive breast cancer or ductal carcinoma in situ.\n3. Bilateral breast cancer.\n4. Any clinical evidence indicating the exist of recurrent diseases after surgery.\n5. History of other malignancy within the last 5 years, excluding cured skin basal cell carcinoma and cervical carcinoma in situ.\n6. Previously received antibody coupled drug (ADC) therapy with topoisomerase inhibitors as effective payloads.\n7. Previously received HER2 targeted therapy.\n8. Active or previously recorded autoimmune or inflammatory diseases.\n9. History of immunodeficiency.\n10. Participants with known or suspected interstitial pneumonia.\n11. Presence of active Hepatitis B.\n12. Known to have active tuberculosis infection.\n13. Uncontrolled infections requiring intravenous injection of antibiotics, antiviral drugs, or antifungal drugs for treatment.\n14. Within the 6 months prior to randomization, there was a history of myocardial infarction, severe\u002Funstable angina, symptomatic congestive heart failure, ≥ Grade 2 supraventricular or ventricular arrhythmias, and any grade of ventricular fibrillation.\n15. Known allergy to any investigational drug or its excipients.\n16. Other medical conditions that would interfere with study participation or follow-up.","FEMALE",{"count":120,"type":22},1000,[26],"It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast cancer with invasive residual cancer after neoadjuvant treatment, and to explore the PK characteristics and immunogenicity of SHR-A1811 and Adebrelimab.",[124],"Triple Negative Breast Cancer","2026-06-25",{"date":58,"type":34},{"date":107,"type":22},{"date":129,"type":22},"2032-12",{"name":40,"class":41},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":42},"100644896","phase-1-a-clinical-study-of-shr-4685-on-safety-tolerability-and-pharmacokinetics-in-participants-with-solid-tumors-100644896","NCT07676903","A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors","A Phase I Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors","Inclusion Criteria:\n\n1. Have fully understood this study and voluntarily signed the informed consent form, with good compliance and cooperation with follow-up;\n2. Age 18-75 years, any gender;\n3. Performance status ECOG score 0 or 1;\n4. Expected survival time greater than 3 months;\n5. Presence of at least one measurable lesion according to RECIST 1.1 criteria;\n6. Have adequate organ function;\n7. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose; and must not be lactating.\n\nExclusion Criteria:\n\n1. Participants who have received any approved anti-tumor drugs (including investigational anti-tumor drugs) within 4 weeks prior to the first dose of the IP;\n2. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 or to the level specified in the inclusion\u002Fexclusion criteria;\n3. Presence of central nervous system (CNS) metastases;\n4. Concurrent active malignancy other than the primary tumor;\n5. History of central nervous system diseases within 12 months prior to screening;\n6. Participants who have undergone major surgery other than diagnostic or biopsy procedures within 28 days prior to the first dose, or who are expected to undergo major surgery during the study;\n7. Participants with active tuberculosis or a history of active tuberculosis infection within ≤48 weeks prior to screening, regardless of treatment;\n8. Presence of any significant clinical or laboratory abnormality that, in the investigator's opinion, affects safety evaluation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive for human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies) with CD4+ T lymphocyte count \\\u003C350 cells\u002FuL; or history of other acquired\u002Fcongenital immunodeficiency diseases; or history of allogeneic bone marrow or solid organ transplantation;\n12. Active chronic hepatitis B or active hepatitis C;\n13. Known history of hypersensitivity to any component of the formulations used in the study;\n14. Other factors, in the opinion of the investigator, that may affect the study results or result in forced halfway termination of this study, such as alcoholism, drug abuse, suffering from other serious diseases (including psychiatric disorders) requiring concomitant treatment, seriously abnormal laboratory test values, family or social factors and other conditions that may affect the safety of the patient or collection of study data.",{"count":139,"type":22},170,[76],"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of SHR-4685 in participants with advanced solid tumors.",[143],"Solid Tumor","2026-06-24",{"date":82,"type":34},{"date":107,"type":22},{"date":148,"type":22},"2028-10",{"name":40,"class":41},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":42},"100644930","phase-3-a-randomized-open-label-controlled-multicenter-phase-iii-clinical-study-of-shr-a1811-in-combination-with-chemotherapy-and-bevacizumab-versus-standard-therapy-as-first-line-treatment-for-advanced-colorectal-cancer-100644930","NCT07676162","A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer","A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With mFOLFOX6 (-1) and Bevacizumab Versus mFOLFOX6 in Combination With Bevacizumab as First-line Treatment for Advanced Colorectal Cancer.","Inclusion Criteria:\n\n1. Subjects voluntarily enroll in the study, sign informed consent, demonstrate good compliance and cooperate with follow-up visits.\n2. Aged between 18 and 75 years inclusive, male or female.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Estimated survival expectancy ≥ 12 weeks.\n5. Histologically or cytologically confirmed colorectal adenocarcinoma.\n6. No prior systemic anti-tumor therapy.\n7. Tumor tissue specimen must be provided, either archived within 1 year prior to first study treatment or newly collected fresh specimen.\n8. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; the measurable lesion shall not have received prior local therapy such as radiotherapy.\n9. Adequate organ function with relevant laboratory tests completed within 7 days before the first study treatment.\n10. Male subjects with fertile female partners and fertile female subjects must use highly effective contraception throughout the study. Fertile female subjects must have a negative serum or urine human chorionic gonadotropin (HCG) test within 7 days prior to first study drug administration and shall not be breastfeeding.\n\nExclusion Criteria:\n\n1. Received systemic anti-tumor therapies (including investigational agents) or major surgery within 4 weeks prior to the first study drug administration; palliative radiotherapy within 2 weeks or surgery within 4 weeks before study treatment initiation.\n2. History of hypersensitivity to monoclonal antibodies or any component of the investigational products to be administered in this study.\n3. Pre-existing peripheral neuropathy of Grade \\>1.\n4. History of thromboembolic disease within 6 months or hemoptysis within 3 months before first study medication. Subjects with muscular venous thrombosis not requiring anticoagulation per investigator's assessment are eligible for enrollment.\n5. CT\u002FMRI evidence of tumor encasement or invasion of major blood vessels.\n6. Non-gastrointestinal bleeding within 6 months prior to first study drug administration, or active peptic ulcer disease.\n7. Uncontrolled hypertension, or medical history of hypertensive crisis or hypertensive encephalopathy.\n8. History of severe cerebrovascular disease.\n9. Unresolved toxicities and\u002For complications from prior interventions that have not recovered to baseline.\n10. Subjects with a history of or current leptomeningeal metastases, or active brain metastases.\n11. Known or suspected interstitial lung disease (ILD); moderate-to-severe pulmonary disease significantly impairing respiratory function or autoimmune\u002Fconnective tissue\u002Finflammatory diseases involving the lung within 3 months before first dosing that may interfere with detection or management of drug-related pulmonary toxicity. Subjects who developed ≥Grade 3 ILD during prior immune checkpoint inhibitor treatment are excluded.\n12. Symptomatic moderate to severe ascites; uncontrolled moderate or greater pleural or pericardial effusion.\n13. Bowel obstruction within 3 months prior to first study treatment, or prior intestinal stent placement with the stent remaining in situ at screening.\n14. Uncontrolled or severe cardiovascular disease, or unstable angina\u002Funstable arrhythmia occurring within 1 month before initiation of study treatment.\n15. Unexplained fever \\>38.5°C at screening or prior to first dose; severe infection (CTCAE Grade \\>2) within 4 weeks before study drug initiation; active pulmonary inflammation on baseline chest imaging, or clinical signs\u002Fsymptoms of infection requiring oral or intravenous antibiotics within 2 weeks before first dosing.\n16. Previous or concurrent diagnosis of other malignant malignancies.\n17. Active hepatitis B or active hepatitis C infection.\n18. History of immunodeficiency including positive HIV test, congenital\u002Facquired immunodeficiency disorders, or prior solid organ transplantation.\n19. Active pulmonary tuberculosis infection within 1 year prior to screening, or prior active pulmonary tuberculosis without standard anti-tuberculosis treatment even if diagnosed more than 1 year ago.\n20. Pregnant, breastfeeding females or females planning pregnancy during the study period.\n21. Uncontrolled psychiatric disorders, known alcohol abuse, illicit drug dependence, incarceration or other conditions that would preclude completion of study procedures.\n22. Any other conditions deemed inappropriate for study participation by the investigator, including clinically significant abnormal laboratory values, familial\u002Fsocial factors or other risks leading to premature study discontinuation or confounding study results.",{"count":158,"type":22},300,[26],"This study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line treatment for advanced colorectal cancer, and to explore the drug's immunogenicity and pharmacokinetic characteristics.",[162],"Advanced Colorectal Cancer","2026-06-23",{"date":82,"type":34},{"date":107,"type":22},{"date":167,"type":22},"2029-09",{"name":40,"class":41},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":64},"100642056","phase-1-a-clinical-study-of-shr-3079-in-b-cell-non-hodgkin-lymphoma-100642056","NCT07661537","A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma","An Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-3079 Injection in Participants With B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Aged ≥ 18 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, expected survival ≥ 3 months;\n3. Histologically confirmed B-NHL;\n4. Participant population: Have received ≥ 1 line of standard anti-tumor treatment, and have not achieved response after the latest treatment or have progressive disease after the treatment;\n5. Have measurable lesions;\n6. Have adequate organ function;\n7. Male participants and female participants of childbearing potential must use adequate and effective contraceptive measures during the study and within 3 months after the last drug administration of SHR-3079. Female participants must not be lactating and must have a negative blood HCG test result within 7 days before the first dose;\n8. Voluntarily sign the ICF, have good compliance, and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) infiltration;\n2. Prior chemotherapy or other anti-lymphoma agents administered within 4 weeks before the first dose of study treatment;\n3. Major surgery within 4 weeks before signing the ICF, or plan to undergo major surgery during the study period;\n4. Receipt of CAR-T therapy or autologous stem cell transplant within 12 weeks prior to enrollment;\n5. Receipt of allogeneic hematopoietic stem cell transplantation;\n6. Prior solid organ transplantation;\n7. Positive hepatitis C virus (HCV) antibody with HCV-RNA copy number above the upper limit of normal of the study site; positive hepatitis B surface antigen \\[HBsAg\\] and\u002For positive hepatitis B core antibody (HBcAb) with HBV DNA copy number above the upper limit of normal of the study site;\n8. Presence of severe disorders involving major organ systems;\n9. Pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention;\n10. Pregnant, lactating women, or women planning to become pregnant;\n11. Have other serious physical or mental illness, laboratory test abnormalities, or other factors that may increase the risk of study participation or interfere with the study results.",{"count":177,"type":22},90,[76],"The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.",[181],"B-cell Non-Hodgkin Lymphoma","2026-06-16",{"date":184,"type":34},"2026-06-22",{"date":186,"type":22},"2026-06",{"date":188,"type":22},"2028-12",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":42},"100641797","phase-1-a-clinical-study-of-shr-5421-in-patients-with-multiple-myeloma-100641797","NCT07652281","A Clinical Study of SHR-5421 in Patients With Multiple Myeloma","An Open-label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-5421 in Patients With Multiple Myeloma","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female.\n2. Expected survival ≥ 3 months.\n3. ECOG performance status 0 or 1.\n4. Diagnosed with active multiple myeloma per IMWG criteria.\n5. Relapsed or refractory multiple myeloma and refractory to the most recent line of therapy.\n6. Disease progression or non-response to the most recent therapy.\n7. Measurable disease as defined by serum\u002Furine M-protein or serum free light chain.\n8. Adequate bone marrow, hepatic, renal, and coagulation function.\n9. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception.\n10. Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Diagnosis of amyloidosis, plasma cell leukemia, Waldenström's macroglobulinemia, or POEMS syndrome.\n2. Central nervous system involvement by tumor.\n3. History of ≥ Grade 3 CRS with prior T-cell redirecting therapy.\n4. Requirement for dialysis or plasmapheresis within 14 days prior to study drug.\n5. Prior treatment-related AEs not recovered to ≤ Grade 1 (except alopecia, peripheral neuropathy, or controlled endocrinopathies).\n6. Concurrent participation in another clinical study.\n7. Prior anti-tumor therapy within specified washout periods.\n8. Major surgery within 28 days prior to informed consent or planned during the study.\n9. Live attenuated vaccine within 4 weeks prior to first dose or planned during the study.\n10. Significant comorbidity that in the investigator's judgment would interfere with study participation or safety.\n11. Active autoimmune disease (except controlled type I diabetes, hypothyroidism, or vitiligo).\n12. Active infection.\n13. Known hypersensitivity or contraindication to SHR-5421.",{"count":198,"type":22},97,[76],"This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).",[202],"Multiple Myeloma","2026-06-11",{"date":205,"type":34},"2026-06-17",{"date":186,"type":22},{"date":208,"type":22},"2029-04",{"name":40,"class":41},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":64},"100625565","phase-3-a-study-of-intravesical-shr-1501-combination-with-bcg-versus-investigator-selected-chemotherapy-in-subjects-with-bcg-unresponsive-nmibc-100625565","NCT07424287","A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","A Multicenter, Randomized, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unresponsive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC) (NiBladder 1)","Inclusion Criteria:\n\n1. Aged at least 18 years, gender is not limited;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n3. Histologic confirmation of high-risk non-muscle invasive bladder cancer (high-grade Ta and\u002For any T1, no carcinoma in situ); BCG-unresponsive;\n4. Cystoscopy within 6 weeks before the randomization shows that the lesion has been completely removed; for T1 stage lesions, pathological results must show the presence of bladder muscle tissue;\n5. Not suitable for or unwilling to undergo radical cystectomy;\n6. Sufficient hematology and organ function.\n\nExclusion Criteria:\n\n1. Previous histopathological diagnosis was muscle-invasive, locally advanced or metastatic urothelial carcinoma (T2 or T3 or T4 or N+ or M+);\n2. Received surgery such as TURBT or radiotherapy for bladder lesions within 2 weeks before the randomization; Major surgery was performed within 28 days before randomization;\n3. Those who have previously received the following treatments and have not experienced disease recurrence or progression before enrolment: a) Intravesical infusion of cytotoxic chemotherapy or other drugs (such as oncolytic viruses), etc; b) Immune checkpoint inhibitors; c) Other investigatory drugs for the treatment of NMIBC;\n4. Those who have previously received immunostimulant therapy;\n5. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration;\n6. Previous medical history or examination suggests active tuberculosis within 1 year prior to the randomization.",{"count":218,"type":22},236,[26],"This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive bladder cancer (NMIBC).",[222],"NMIBC","2026-05-29",{"date":225,"type":34},"2026-06-02",{"date":186,"type":22},{"date":228,"type":22},"2030-06",{"name":40,"class":41},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":64},"100598241","phase-1-a-clinical-study-of-shr-4506-injection-in-patients-with-malignant-tumors-100598241","NCT07068932","A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors","Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4506 Injection in Patients With Malignant Tumors","Inclusion Criteria:\n\n1. Age ≥18 years, any gender.\n2. ECOG performance status 0-1.\n3. Histologically or cytologically confirmed malignant tumor patients who have failed standard therapy, or are intolerant to standard therapy, or have no standard treatment available.\n4. Adequate organ function.\n5. Voluntary participation in this clinical trial, with full understanding of study procedures and ability to provide written informed consent.\n6. Expected survival ≥12 weeks.\n7. Patients in the dose-expansion phase must have measurable lesions.\n8. Agreement to use contraception from the time of signing the informed consent to at least 60 days after the last dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Prior treatment with the same class of investigational drug.\n2. Confirmed or suspected central nervous system (CNS) tumor involvement.\n3. Uncontrolled tumor-related pain.\n4. Active autoimmune disease, history of immunodeficiency (including primary or secondary, e.g., HIV infection), or autoimmune disorders requiring systemic therapy.\n5. Clinically significant cardiovascular disease history.\n6. Known hypersensitivity to any component of the investigational drug.\n7. Major surgery or significant trauma within 4 weeks prior to the first dose of the investigational drug; diagnostic or superficial surgery within 7 days before the first dose; or planned major surgery during the study period.\n8. Adverse events from prior therapy have not recovered to ≤ CTCAE Grade 1.\n9. Severe infection within 4 weeks before the first dose, or active infection within 2 weeks.\n10. History of cerebrovascular accident within 6 months before the first dose of the investigational drug.\n11. Patients with other active malignancies within 2 years prior to the first dose or concurrent malignancies.\n12. Patients with any other condition judged by the investigator that makes the patient unsuitable for participation in the study.",{"count":238,"type":22},102,[76],"The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).",[242],"Malignant Tumors of Adults","2026-05-14",{"date":245,"type":34},"2026-05-18",{"date":247,"type":34},"2025-07-22",{"date":249,"type":22},"2027-08",{"name":40,"class":41},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":42},"100630595","phase-2-a-phase-ii-clinical-trial-of-shr-1826-for-non-small-cell-lung-cancer-100630595","NCT07489716","A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years\n2. ECOG performance status score of 0 or 1;\n3. Histopathologically confirmed advanced or metastatic non-small cell lung cancer;\n4. Participants must provide archived or fresh tumor tissue;\n5. Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease;\n6. At least one measurable lesion according to RECIST v1.1 criteria;\n7. Expected survival ≥3 months;\n8. Adequate organ function;\n\nExclusion Criteria:\n\n1. Central nervous system metastasis or meningeal metastasis with clinical symptoms\n2. History of or concurrent other malignancies;\n3. Untreated spinal cord compression ;\n4. Uncontrolled tumor-related pain;\n5. Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1;\n6. History of interstitial lung disease;\n7. Severe cardiovascular\u002Fcerebrovascular diseases;",{"count":177,"type":22},[25],"This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.",[262],"Non-Small Cell Lung Cancer","2026-05-12",{"date":265,"type":34},"2026-05-13",{"date":267,"type":34},"2026-04-29",{"date":188,"type":22},{"name":40,"class":41},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":64},"100629717","phase-1-a-study-of-shr-2524-plus-bevacizumab-in-the-first-line-treatment-of-advanced-hepatocellular-carcinoma-100629717","NCT07478302","A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma","To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial","Inclusion Criteria:\n\n1. ≥ 18 years old;\n2. Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis;\n3. The Barcelona clinical liver cancer stage was B or C;\n4. Has not previously received systemic antitumor therapy for HCC;\n5. At least one measurable lesion according to RECIST v1.1 criteria;\n6. Child-Pugh score of A or B7 ;\n7. ECOG score 0 -1;\n8. The expected survival time was ≥12 weeks;\n9. The major organs functioned well;\n10. Has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, and fibrolamellar hepatocellular carcinoma confirmed by histology or cytology;\n2. Patients with active malignant tumors other than HCC within 5 years or at the same time; Localized tumors that had been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, and breast cancer in situ, could be enrolled;\n3. Previous allogeneic organ transplantation (e.g., liver transplantation);\n4. The current liver tumor burden is greater than 50% of the total liver volume;\n5. CTCAE grade 3 bleeding had occurred within 6 months or CTCAE grade 2 nongastrointestinal bleeding had occurred within 3 months before the first dose;\n6. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before the first dose;\n7. Major vascular disease had occurred within 6 months before the first dose;\n8. Current concomitant interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy;\n9. Innate or acquired immune deficiency (such as HIV infection);\n10. Severe infection occurred within 28 days before the first dose.",{"count":278,"type":22},36,[76],"This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.",[282],"Advanced Unresectable Hepatocellular Carcinoma",{"date":284,"type":34},"2026-05-01",{"date":286,"type":34},"2026-04-14",{"date":288,"type":22},"2027-12",{"name":40,"class":41},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":64},"100627906","phase-2-a-clinical-study-of-adebrelimab-in-combination-with-shr-8068-and-chemoradiotherapy-as-perioperative-therapy-for-locally-advanced-rectal-cancer-100627906","NCT07454720","A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II\u002FIII Clinical Study of Adebrelimab Combined With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Resectable Rectal Cancer","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.\n2. Male or female ≥ 18 years old and ≤75 years old.\n3. ECOG performance status of 0-1.\n4. An assessment of resectable locally advanced rectal.\n5. Has not received any anti-tumor treatment for rectal cancer.\n6. With a life expectancy of ≥2 years.\n7. Male participants whose partners are fertile women and fertile female participants must take effective contraceptive measures together with their partners from the time of signing the informed consent form until 6 months after the last administration of the investigational drug or the last radiotherapy. Female participants with fertility must have a negative serum or urine test for human chorionic gonadotropin (HCG) within 7 days before the first administration of the drug (if the serum HCG test is positive, pregnancy should be ruled out and further discussion with the sponsor should be conducted), and they must be not in the lactation period.\n\nExclusion Criteria:\n\n1. Patients with rectal cancer who have experienced local recurrence after previous treatment.\n2. Patients with concurrent colon tumors.\n3. Patients with initially unresectable colorectal cancer as evaluated by researchers or those whose condition is determined by researchers to be intolerant to surgery.\n4. Clinical or imaging examinations suggest the presence of intestinal obstruction or perforation, or those assessed by researchers as having a relatively high risk of perforation or bleeding.\n5. With distant metastases.\n6. Imaging examination of rectal cancer indicated positive lateral lymph nodes.\n7. Having received surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. for tumors.\n8. Female participants who are pregnant, breastfeeding or planning to become pregnant during the study period.\n9. There are uncontrollable mental illnesses and other circumstances known to affect the completion of the research procedures, such as alcohol abuse, drug abuse or drug abuse, and criminal detention.\n10. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.",{"count":298,"type":22},165,[25,26],"The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.",[302],"Locally Advanced Resectable Rectal Cancer",{"date":304,"type":34},"2026-05-05",{"date":306,"type":34},"2026-03-23",{"date":308,"type":22},"2035-11",{"name":40,"class":41},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":42},"100563630","phase-3-a-clinical-study-of-shr-8068-combined-with-adebrelimab-and-bevacizumab-versus-sintilimab-or-atezolizumab-combined-with-bevacizumab-for-the-treatment-of-advanced-hepatocellular-carcinoma-100563630","NCT06618664","A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma","A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent.\n2. ≥ 18 years old, both male and female.\n3. Unresectable locally advanced or metastatic HCC confirmed by histopathologically\u002Fcytologically.\n4. At least one measurable lesion based on RECIST v1.1 criteria.\n5. Barcelona clinic liver cancer: Stage B or C.\n6. No previous systemic antitumor therapy for HCC.\n7. ECOG PS of 0-1.\n8. Child-Pugh score of A or B7.\n9. Expected survival period ≥ 12 weeks.\n10. Adequate organ function.\n11. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.\n\nExclusion Criteria:\n\n1. Hepatic cholangiocarcinoma, mixed hepatocellular carcinoma -cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma.\n2. Patients with other malignancies currently or within the past 5 years.\n3. With known severe allergic reactions to any other monoclonal antibodies.\n4. Patients with known CNS metastasis or hepatic encephalopathy.\n5. Patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants.\n6. Patients with symptomatic ascites or pleural effusion.\n7. Patients with hypertension which cannot be well controlled by antihypertensives.\n8. Uncontrolled cardiac diseases or symptoms.\n9. Known hereditary or acquired bleeding (e.g., coagulopathy) or a tendency to clot (e.g., hemophiliacs).\n10. Major vascular disease occurred in the 6 months before randomization.\n11. Gastrointestinal perforation or gastrointestinal fistula within 6 months before randomization.\n12. Major surgery within 28 days before randomization or expected to require major surgery during the study period.\n13. Active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or WBC \\> 15×109\u002FL at baseline.\n14. Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known HBV infection, known HCV infection.\n15. Patients who received live vaccines within 28 days before randomization, or are expected to be vaccinated during the treatment period\n16. Patients with other potential factors that may affect the study results.",{"count":318,"type":22},590,[26],"THis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.",[322],"Advanced Hepatocellular Carcinoma","2026-04-28",{"date":325,"type":34},"2026-05-04",{"date":327,"type":34},"2024-10-28",{"date":329,"type":22},"2030-12",{"name":40,"class":41},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":42},"100615912","phase-1-a-study-of-shr-4375-injection-in-combination-with-other-antitumor-therapies-in-patients-with-solid-tumors-100615912","NCT07298772","A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","A Phase Ib\u002FII, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Voluntary participation and written informed consent.\n2. 18-75 years older, no gender limitation.\n3. Eastern Cooperative Oncology Group (ECOG) score: 0-1.\n4. With a life expectancy ≥ 12 weeks.\n5. Patients with advanced solid tumors confirmed by cytology or histology who have failed or are intolerant to standard treatment and have no standard treatment.\n6. Be able to provide fresh or archived tumour tissue.\n7. At least one measurable lesion according to RECIST v1.1.\n8. Adequate bone marrow and organ function.\n9. Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. There are components of neuroendocrine carcinoma or sarcoma in the histopathological type.\n2. Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks prior to the first administration of the study; Palliative radiotherapy was received within 2 weeks before the first administration.\n3. Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such vaccines will be needed during the treatment period.\n4. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration.\n5. Previously received antibody-drug conjugate therapy containing topoisomerase I inhibitors.\n6. Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study.\n7. Suffering from other active malignant tumors within 3 years or at the same time.\n8. Symptomatic or active central nervous system tumor metastasis.\n9. Accompanied by uncontrolled tumor related pain.\n10. Subjects who have experienced severe infections within 30 days prior to their first medication use.\n11. History of interstitial pneumonia\u002Fnon infectious pneumonia requiring hormone therapy in the past.\n12. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1.\n13. Active hepatitis B or active hepatitis C.\n14. Clinically significant bleeding symptoms or significant bleeding tendency occurred within 1 month before the first medication.\n15. Moderate and severe ascites with clinical symptoms; Uncontrolled or moderate to excessive pleural effusion and pericardial effusion.\n16. Uncontrollable mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention.\n17. Per the investigator's judgment, there are any other circumstances that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate.",{"count":339,"type":22},198,[76,25],"This is an open label, multi-center, Phase Ib\u002FII study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.",[343],"Advanced Solid Tumor","2026-04-27",{"date":284,"type":34},{"date":347,"type":34},"2026-01-07",{"date":62,"type":22},{"name":40,"class":41},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":42},"100553337","phase-1-a-clinical-study-of-shr-9539-in-patients-with-multiple-myeloma-100553337","NCT06484777","A Clinical Study of SHR-9539 in Patients With Multiple Myeloma","An Open-label, Multi-center Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma","Inclusion Criteria:\n\n1. Age ≥ 18 years on day of signing the Informed Consent Form;\n2. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale；\n3. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria ；\n4. Have a life expectancy of at least 3 months；\n5. Male and female subjects with fertility must agree to use efficient contraceptive measures with their partners within 3 months after the last administration of the test drug from the time of signing the informed consent form, and have no fertility plan and avoid donating sperm \u002F eggs. The pregnancy test during the screening period must be negative.\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) involvement of MM；\n2. Diagnosis of amyloidosis, plasma cell leukemia, Wahl's macroglobulinemia, or POEMS syndrome;\n3. Prior Grade 3 or higher CRS (Per ASTCT standards) related to any T cell redirection (eg, CD-3 redirection technology or CAR-T cell therapy).\n4. Have other factors that may force the termination of the study, e.g., non-compliance with the protocol, other serious illnesses (including psychiatric illnesses) that require comorbid treatment, serious laboratory abnormalities, associated family or social factors, which would affect the safety of the subjects or the collection of data and samples, as determined by the investigator.",{"count":358,"type":22},138,[76],"This study is a multicenter, open-label, dose-escalation\u002Fdose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.",[202],"2026-04-13",{"date":364,"type":34},"2026-04-16",{"date":366,"type":34},"2024-08-07",{"date":368,"type":22},"2027-07-31",{"name":40,"class":41},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":42},"100607025","phase-3-a-study-of-shr-a2009-combined-with-aumolertinib-versus-aumolertinib-for-first-line-treatment-in-egfr-mutated-advanced-or-metastatic-nsclc-100607025","NCT07183189","A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations","Inclusion Criteria:\n\n1. Age 18 to 75 years (inclusive) at the time of signing informed consent, regardless of gender.\n2. Subjects with histologically or cytologically confirmed locally advanced, metastatic, or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.\n3. No prior systemic therapy for locally advanced, metastatic, or recurrent non-small cell lung cancer.\n4. At least one measurable tumor lesion according to RECIST v1.1.\n5. ECOG performance status of 0 or 1.\n6. Expected survival time ≥12 weeks.\n7. Adequate bone marrow and organ function.\n8. Subjects must provide informed consent prior to the trial and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed combined small cell lung cancer (SCLC), neuroendocrine carcinoma, sarcomatoid carcinoma, or carcinosarcoma components.\n2. Subjects with a history of leptomeningeal metastasis, brainstem metastasis, or spinal cord metastasis.\n3. Subjects with uncontrolled tumor-related pain, as determined by the investigator.\n4. Clinically uncontrolled third-space fluid accumulation, as determined by the investigator.\n5. Insufficient time interval between prior antitumor therapy and the first dose administration.\n6. Major organ surgery or significant trauma within 4 weeks prior to the first dose of the study drug.\n7. History of other malignancies within ≤5 years prior to the first dose.\n8. Subjects with a history of interstitial lung disease, or imaging at screening suggestive of suspected interstitial lung disease; or other moderate to severe pulmonary diseases severely affecting lung function.\n9. Severe cardiovascular or cerebrovascular diseases.\n10. Any severe or uncontrolled ocular lesions that, in the physician's judgment, may increase the patient's safety risk.\n11. Refractory nausea, vomiting, chronic gastrointestinal diseases, etc.\n12. Severe infections within 4 weeks prior to the first dose.\n13. Subjects with arterial\u002Fvenous thromboembolic events within 6 months prior to the first dose of the study drug.\n14. Active tuberculosis infection.\n15. History of immunodeficiency, including positive HIV test.\n16. Active hepatitis B or hepatitis C.\n17. Prior allogeneic hematopoietic stem cell transplantation or organ transplantation.\n18. History of severe allergic reactions to aumolertinib or other monoclonal antibodies, or hypersensitivity to any component of SHR-A2009.\n19. Known history of alcohol or drug dependence or drug abuse.\n20. Psychiatric disorders or poor compliance.",{"count":378,"type":22},576,[26],"This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.",[382],"Non-small Cell Lung Cancer","2026-04-09",{"date":286,"type":34},{"date":386,"type":34},"2025-10-30",{"date":129,"type":22},{"name":40,"class":41},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":118,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":42},"100625139","phase-3-a-study-of-shr-a2102-versus-investigators-choice-of-chemotherapy-in-patients-with-platinum-based-chemotherapy-and-pd-l1-inhibitor-treatment-failed-recurrent-or-metastatic-cervical-cancer-100625139","NCT07418749","A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","An Open-label, Randomized, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. Participate in the study voluntarily, sign the informed consent form.\n2. Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that is deemed unsuitable for radical surgery and\u002For radical radiotherapy or chemoradiotherapy.\n3. Provide primary or metastatic tumor samples.\n4. At least one measurable lesion (RECIST version 1.1).\n5. ECOG 0\\~ 1.\n6. With adequate organ functions.\n7. Expected overall survival is ≥12 weeks.\n\nExclusion Criteria:\n\n1. With known untreated or active central nervous system (CNS) tumor metastasis, or a history of or current leptomeningeal metastasis.\n2. With symptomatic, poorly controlled, or moderate-to-severe pleural effusion, pericardial effusion, or ascites.\n3. With a history of or concurrent other malignant tumor(s).\n4. Participants with gastrointestinal perforation or fistula, urogenital fistula, or those at risk of fistula within 3 months prior to randomization.\n5. With known or suspected interstitial lung disease.\n6. With intestinal obstruction or signs\u002Fsymptoms suggestive of intestinal obstruction within 3 months prior to randomization.\n7. With poorly controlled cardiac clinical symptoms or diseases.\n8. Experienced arterial\u002Fvenous thromboembolic events within 3 months prior to randomization.\n9. With severe infections occurring within 1 month prior to randomization.\n10. With active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] test and hepatitis B virus \\[HBV\\] DNA ≥500 IU\u002FmL at screening) or active hepatitis C (defined as positive hepatitis C virus antibody \\[HCV-Ab\\] test and detectable hepatitis C virus \\[HCV\\] RNA at screening).\n11. With active tuberculosis infection within 1 year prior to randomization, or a history of active tuberculosis infection more than 1 year ago without proper treatment.\n12. With a history of immunodeficiency, including a positive human immunodeficiency virus (HIV) test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.\n13. Have received systemic anti-tumor therapy within 28 days prior to randomization.\n14. With uncontrolled psychiatric disorders, or known history of alcoholism, drug abuse, or substance dependence, incarceration, or other conditions that may affect the completion of study procedures.\n15. Any other condition that, in the judgment of the investigator, may increase the risk associated with study participation, interfere with the interpretation of study results, or make the participant unsuitable for the study.",{"count":397,"type":22},398,[26],"The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.",[401,402],"Recurrent Cervical Cancer","Metastatic Cervical Cancer","2026-04-03",{"date":405,"type":34},"2026-04-06",{"date":407,"type":34},"2026-03-30",{"date":188,"type":22},{"name":40,"class":41},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":428,"locationsCount":64},"100627618","phase-2-a-study-of-shr-a1904-in-previous-systemic-treatment-failed-biliary-tract-cancer-100627618","NCT07450976","A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","A Phase IIa\u002FIIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","Inclusion Criteria:\n\n1. Age 18-75 years old (including both ends), male or female;\n2. ECOG-PS score: 0 or 1;\n3. Expected survival ≥ 12 weeks;\n4. Locally advanced or metastatic biliary tract cancer confirmed by histopathology or cytology;\n5. CLDN18.2 positive expression;\n6. Subjects who failed or intolerance after systemic chemotherapies;\n7. According to the RECIST v1.1 standard, the subjects had at least one measurable lesion;\n8. The main organ function is normal, in line with the program requirements;\n9. Consent to contraception.\n\nExclusion Criteria:\n\n1. Received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration;\n2. Other active malignancies within 5 years or at the same time;\n3. Subjects with a history or evidence of brain metastasis or meningeal metastasis;\n4. With acute or chronic uncontrolled pancreatitis or Child-Pugh liver function grade C;\n5. Severe trauma or major surgery was performed within 4 weeks before the first administration;\n6. To study the severe heart disease within 6 months before the first administration;\n7. Patients with clinical symptoms and uncontrolled moderate and above pleural effusion, ascites or pericardial effusion, requiring therapeutic puncture drainage;\n8. Severe infection symptoms occurred within 2 weeks before the first administration;\n9. Known hereditary or acquired bleeding and thrombotic tendency;\n10. Congenital or acquired immune defects;\n11. The subjects had severe and uncontrollable concomitant diseases;\n12. Cerebral infarction, pulmonary embolism or deep vein thrombosis occurred within 6 months before the first administration of the study.",{"count":418,"type":22},151,[25],"This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.",[422],"Biliary Tract Cancer",{"date":424,"type":34},"2026-03-31",{"date":426,"type":34},"2026-03-25",{"date":329,"type":22},{"name":40,"class":41},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":64},"100610596","phase-1-a-ibii-phase-clinical-study-on-the-safety-tolerability-and-efficacy-of-shr-9839sc-in-combination-anti-tumor-therapy-in-patients-with-solid-tumors-100610596","NCT07229638","A IB\u002FII Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","An Open-label, Multicenter Phase IB\u002FII Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","Inclusion Criteria:\n\n1. Able to provide informed consent, has signed the IRB\u002FEC-approved informed consent form with the date indicated, and is willing and able to comply with treatment plan visits, examinations, and other procedural requirements;\n2. Age 18-70 years (inclusive) at the time of signing the informed consent form, no gender restriction;\n3. ECOG performance status of 0 or 1;\n4. Expected survival ≥12 weeks;\n5. At least one measurable lesion according to RECIST v1.1 criteria;\n6. Subjects must provide formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimens. For subjects unable to provide tumor tissue as required, enrollment should be determined after discussion with the sponsor;\n7. Major organ function must meet standards (no use of blood components or growth factors within 14 days before the first dose to correct abnormalities); test results must be completed within 7 days prior to the first study treatment;\n8. Female subjects of reproductive potential must agree to use highly effective contraception starting from the signing of the informed consent form, throughout the study treatment period, and for 9 months after the last administration of the investigational product, and must avoid donating eggs during this period. Male subjects with partners of reproductive potential must agree to use highly effective contraception starting from the first dose of the investigational product, throughout the study treatment period, and for 6 months after the last administration of the investigational product, and must avoid donating sperm during this period. Female subjects must not be breastfeeding and must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before the first dose (if the serum pregnancy test is positive, pregnancy must be excluded and enrollment confirmed after discussion with the sponsor).\n\nExclusion Criteria:\n\n1. Patients with active central nervous system (CNS) metastases or leptomeningeal metastases (including a history of such);\n2. Patients with other malignancies within 3 years before the first dose, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, locally resected prostate cancer, ductal carcinoma in situ post-surgery, or papillary thyroid carcinoma post-surgery (hormonal therapy for non-metastatic prostate or breast cancer is allowed);\n3. Patients deemed by the investigator to have uncontrolled tumor-related pain. Subjects requiring analgesic treatment must have a stable analgesic regimen before entering the study; symptomatic lesions suitable for palliative radiotherapy should be treated prior to study entry;\n4. Patients with severe cardiovascular or cerebrovascular disease;\n5. Patients with clinically symptomatic moderate or severe ascites (i.e., requiring therapeutic paracentesis or drainage within 2 weeks before the study treatment; subjects with only minimal ascites shown on imaging without clinical symptoms may be enrolled); uncontrolled or moderate-to-large pleural effusion or pericardial effusion;\n6. Patients with a history of interstitial pneumonia, including idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonia, radiation-induced pneumonia requiring steroid treatment, or those with suspected interstitial pneumonia on imaging at screening, or in whom interstitial pneumonia cannot be excluded (subjects with only fibrotic radiation pneumonitis in the radiation field may participate); or patients with respiratory failure, severe asthma, severe chronic obstructive pulmonary disease, or other serious lung diseases significantly affecting pulmonary function; or those who have previously undergone total lung resection;\n7. Patients with severe infection within 4 weeks before the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infection complications requiring hospitalization; active infections of CTCAE grade ≥2 requiring systemic antibiotic therapy within 2 weeks before the first dose; subjects receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection) may be enrolled;\n8. History of immunodeficiency, including positive HIV test; presence of active hepatitis B (HBsAg positive during the screening period, and DNA quantification ≥1000 copies\u002Fml or 500 IU\u002Fml) or hepatitis C (anti-HCV positive and HCV RNA positive);\n9. Active pulmonary tuberculosis infection within one year prior to enrollment as indicated by medical history or imaging, or a history of active pulmonary tuberculosis more than one year ago that was not formally treated;\n10. Previous adverse reactions to anti-tumor treatments that have not recovered to CTCAE ≤ grade 1 (except for alopecia, grade 2 peripheral neuropathy meeting the enrollment criteria, or other situations judged by the investigator not to affect study drug treatment);\n11. Systemic anti-tumor treatment (including chemotherapy, biological therapy, targeted therapy, immunotherapy, radical radiotherapy, etc.) within four weeks prior to starting the study treatment;\n12. Chest radiotherapy \\>30 Gy within 24 weeks prior to first use of the study drug, non-chest radiotherapy \\>30 Gy within four weeks prior to first use (subjects who completed brain metastasis radiotherapy within 14 days prior to first dose may be enrolled), and palliative radiotherapy ≤30 Gy within 14 days prior to first use;\n13. Major organ surgery within 4 weeks prior to first use of the study drug (excluding biopsy), significant trauma, or planned elective surgery during the trial; minor traumatic surgery (biopsy, endoscopy, and drainage procedures) within seven days prior to first use of the study drug;\n14. Within 3 months prior to the start of the study, participants who had intestinal obstruction or symptoms and signs of intestinal obstruction are excluded. However, if they have undergone surgical or other treatments and the obstruction has been completely relieved, they may be screened; those who have previously received intestinal stent placement and whose stent has not been removed by the screening period are also excluded;\n15. Severe gastrointestinal disorders, including but not limited to grade ≥2 inflammation, diarrhea, bleeding, obstruction, perforation, or fistula (except for hemorrhoidal bleeding or cases presenting only as positive fecal occult blood, which may be included);\n16. Use of live attenuated vaccines within 28 days before the first administration of the study drug, or anticipated need for live attenuated vaccines during the study treatment;\n17. Pregnant or breastfeeding women, or women planning to become pregnant during the study period and within 7 months after the last administration of the study drug;\n18. History of severe allergic reactions to any component of the proposed study drug;\n19. According to the investigator's judgment, participants who have other factors that may affect the study results or potentially lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, domestic or social factors, and other circumstances that may impact participant safety or the collection of study data.",{"count":437,"type":22},70,[76,25],"This study is an open-label, multi-center Phase IB\u002FII clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.",[143],"2026-03-18",{"date":443,"type":34},"2026-03-20",{"date":445,"type":34},"2026-02-27",{"date":447,"type":22},"2027-06",{"name":40,"class":41},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":456,"sex":17,"minAge":18,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":42},"100624820","phase-1-a-phase-i-study-of-single-subcutaneous-dose-of-shr-1894-in-healthy-subjects-100624820","NCT07414602","A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Doses of SHR-1894 in Healthy Subjects","Inclusion Criteria:\n\n1. The subject has voluntarily provided written informed consent, fully understands the purpose and significance of this trial, and is willing to comply with the study protocol.\n2. Healthy male or female subjects, aged 18 to 45 years (inclusive) at the time of signing the informed consent form.\n3. Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body mass index (BMI) = weight (kg)\u002Fheight\\^2 (m²). BMI between 19 and 26 kg\u002Fm², inclusive.\n4. Subjects with no abnormalities, or only minor abnormalities deemed clinically insignificant by the investigator, in physical examination, vital signs, 12-lead electrocardiogram (ECG), posteroanterior and lateral chest radiographs, abdominal ultrasound, and laboratory tests during the screening and baseline periods.\n5. Female subjects of childbearing potential and male subjects with partners of childbearing age must have been using highly effective contraception for at least 2 weeks prior to signing the informed consent form. They must be willing to either abstain from sexual intercourse or agree to continue using highly effective contraception from the time of signing the informed consent until the end of the follow-up period, and must have no plans for conception or donation of sperm\u002Fova.\n\nExclusion Criteria:\n\n1. Subjects with a history or current diagnosis of any clinically significant disease, as determined by the investigator, involving the urinary, circulatory, endocrine, neurological, digestive, respiratory, hematopoietic, immune systems, or psychiatric and metabolic disorders.\n2. Subjects who, in the investigator's judgment, have any condition or disease that may affect the absorption, metabolism, and\u002For excretion of the investigational drug.\n3. Subjects who have experienced severe infection, severe trauma, or undergone major surgery within 1 month prior to the screening period; or who plan to undergo surgery during the trial period.\n4. Subjects with a known allergy to the investigational drug or any of its components, or with a history of atopy (e.g., asthma, eczema).\n5. Subjects will be excluded if they meet any of the following criteria: Use of any medication (including prescription drugs, over-the-counter medications, Chinese herbal medicines, dietary supplements, and vitamin A and its derivatives, with the exception of other routine vitamins and occasional use of acetaminophen) within 2 weeks prior to screening.Any medication taken within 5 half-lives prior to screening (whichever period is longer).Planned use of any non-study medication during the trial period.\n6. Subjects will be excluded for any of the following: Participation in any other drug or medical device clinical trial within 3 months prior to screening or planned participation during the study period.Any prior investigational drug taken within 5 half-lives prior to screening (whichever washout period is longer).\n7. Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test result at screening or baseline.\n8. Subjects with a history of blood donation (≥ 400 mL) or significant blood loss within 8 weeks prior to screening, or who received a blood transfusion within 4 weeks prior to screening or baseline; or who intend to donate blood during the trial period.\n9. Subjects who have received any vaccination within 2 weeks prior to screening or who plan to receive any vaccination during the trial.\n10. Subjects with a history of significant smoking (averaging \\>5 cigarettes per day) within 4 weeks prior to screening, or who are unable to abstain from using any tobacco products during the trial period.\n11. Subjects meeting any of the following criteria will be excluded: Average daily alcohol intake exceeding 15 g (equivalent to 450 mL of beer, 150 mL of wine, or approximately 50 mL of low-alcohol spirits) within 4 weeks prior to screening.Inability to abstain from alcohol consumption during the trial period.A positive alcohol breath test at baseline.\n12. Subjects with a history of illicit drug use or substance abuse\u002Fdependence prior to screening; or a positive urine drug test at baseline.\n13. Subjects with special dietary requirements that prevent compliance with the standardized diet.\n14. Subjects with difficult venous access or whose physical condition cannot tolerate frequent blood sampling.",true,"45 Years",{"count":459,"type":22},40,[76],"The Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1894 in healthy subjects.",[463],"Dermatitis","2026-03-16",{"date":441,"type":34},{"date":464,"type":34},{"date":468,"type":22},"2026-12",{"name":40,"class":41},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":487,"locationsCount":42},"100598455","phase-2-a-phase-ii-study-of-shr-8068-injection-in-combination-with-anti-tumor-therapies-in-colorectal-cancer-100598455","NCT07071714","A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.\n2. Male or female ≥ 18 years old and ≤75 years old.\n3. ECOG performance status of 0-1.\n4. Part A with a life expectancy of ≥2 years. Part B with a life expectancy of ≥12 weeks.\n5. Need to provided tumor tissue samples for genetic testing.\n\nExclusion Criteria:\n\n1. Part B: Accompanied by untreated or active central nervous system (CNS) metastases. Subjects with a history or current history of meningeal metastasis.\n2. Part B: Systemic antitumor therapy was received 4 weeks before the start of the study.\n3. Part B: Palliative radiotherapy was completed within 14 days before the first dose.\n4. Toxicity and\u002For complications from previous interventions did not return to NCI-CTCAE level ≤1 or exclusion criteria.\n5. Subjects with known or suspected interstitial pneumonia.\n6. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion.\n7. Have poorly controlled or severe cardiovascular disease.\n8. Subjects with active hepatitis B or active hepatitis C.\n9. A history of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation.\n10. The presence of uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention.\n11. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.",{"count":478,"type":22},200,[25],"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.",[482],"Colorectal Cancer",{"date":441,"type":34},{"date":247,"type":34},{"date":486,"type":22},"2031-10",{"name":40,"class":41},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":42},"100611362","phase-1-phase-ibii-clinical-study-of-shr-8068-combined-with-adebrelimab-and-other-anti-tumor-drugs-in-the-treatment-of-advanced-renal-cell-carcinom-100611362","NCT07239596","Phase Ib\u002FII Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","An Open, Multicenter Phase Ib\u002FII Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Age 18 to 75 years old (including boundary values)\n2. Volunteer to participate in this clinical study and sign informed consent;\n3. ECOG score 0-1;\n4. Expected survival ≥3 months;\n5. Patients with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology;\n6. Tumor tissue samples must be provided for testing\n7. There is at least one measurable or evaluable lesion that meets the RECIST 1.1 criteria;\n8. Adequate bone marrow and organ function.\n\nExclusion Criteria:\n\n1. Have previously used or are currently using HIF inhibitors.\n2. Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks prior to the first administration of the study; Palliative radiotherapy was received within 2 weeks before the first administration.\n3. Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such vaccines will be needed during the treatment period.\n4. Undergoing major surgical treatment within a certain period of time after the first administration of medication (excluding diagnosis) or expecting major surgical treatment during the study period.\n5. There are severe gastrointestinal function abnormalities in clinical practice, which may affect the intake, transportation or absorption of drugs.\n6. Suffering from other active malignant tumors within 3 years or at the same time.\n7. Patients who have received organ transplants in the past (excluding corneal transplants).\n8. A clinically significant thrombotic or embolic event occurred within 6 months prior to the first administration of the drug.\n9. There are clinical symptoms or diseases of the heart that are not well controlled.\n10. Active tuberculosis.\n11. Moderate and severe ascites with clinical symptoms; Uncontrolled or moderate to excessive pleural effusion and pericardial effusion.\n12. The toxicity and\u002For complications of previous intervention measures have not been restored to the level of NCI-CTCAE≤1 or the inclusion and exclusion criteria.\n13. Subjects with active hepatitis B or active hepatitis C.\n14. As determined by the researcher, there are other factors that may affect the research results or lead to the forced termination of this study midway",{"count":496,"type":22},139,[76,25],"This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma",[500],"Advanced Renal Cell Carcinoma","2026-03-12",{"date":464,"type":34},{"date":504,"type":34},"2026-01-06",{"date":329,"type":22},{"name":40,"class":41},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":42},"100623200","phase-3-a-trial-of-shr-a2102-with-adebrelimab-in-locally-advanced-or-metastatic-urothelial-carcinoma-100623200","NCT07393542","A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","An Open Label, Randomized, Multicenter, Phase III Study of SHR-A2102 in Combination With Adebrelimab Versus Gemcitabine in Combination With Cisplatin\u002FCarboplatin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (NEC-UC2)","Inclusion Criteria:\n\n1. Be able to sign the informed consent form in writing.\n2. Female or male, 18 to 80 years of age (both inclusive).\n3. ECOG performance status of 0 or 1.\n4. Expected survival of≥ 3 months.\n5. Histologically confirmed diagnosis of urothelial carcinoma with radiographic or other confirmation of locally advanced unresectable or metastatic disease.\n6. No prior systemic therapy for locally advanced or metastatic disease.\n7. Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.\n8. According to RECIST v1.1, there must be at least one measurable lesion;\n9. Tolerant to cisplatin or carboplatin.\n10. Adequate organ functions.\n11. Agree to use medically approved contraceptive measures.\n\nExclusion Criteria:\n\n1. Planned to receive any other anti-tumor therapy during the study.\n2. Received other investigational products or treatments not yet marketed within 4 weeks.\n3. Have received systemic anti-tumor treatment within 4 weeks;have received prior anti-tumor Chinese patent medicine treatment within 2 weeks; palliative radiotherapy or local therapy within 2 weeks.\n4. Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: targeting Nectin-4; containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor.\n5. Prior treatment with immune checkpoint inhibitors.\n6. Major surgical procedure other than diagnostic or biopsy within 4 weeks, requiring elective surgery during the trial.\n7. Active autoimmune disease requiring systemic treatment within 2 years.\n8. Have experienced adverse events caused by previous anti-tumor treatments that have not recovered to grade ≤1 as per NCI-CTCAE v5.0.\n9. Uncontrolled central nervous system metastases or carcinomatous meningitis.\n10. Subjects with clinical symptoms or serous cavity effusion requiring puncture drainage.\n11. Other malignancies within 5 years.\n12. History of clinically significant pulmonary disease or any such disease suggested by chest imaging at screening.\n13. Serious infections requiring intravenous antibiotics, antivirals, or antifungals for control.\n14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n15. History of immunodeficiency, or history of organ transplant.\n16. Have experienced arteriovenous thrombosis or cardiovascular and cerebrovascular accidents within 6 months.\n17. Subjects with clinically significant hemorrhage within 3 months.\n18. Glycosylated hemoglobin (HbA1c) ≥ 8%.\n19. Have serious cardiovascular and cerebrovascular diseases.\n20. Allergic reaction to any component of the study treatment.\n21. Subjects with active pulmonary tuberculosis.\n22. Have severe dry eye, active keratitis, or corneal ulcer, or other conditions.\n23. Female Subjects who are pregnant or planning to become pregnant during the study.\n24. Other conditions unsuitable into the study.",{"count":515,"type":22},462,[26],"The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin\u002Fcarboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.",[519],"Locally Advanced or Metastatic Urothelial Carcinoma",{"date":521,"type":34},"2026-03-03",{"date":523,"type":34},"2026-02-12",{"date":228,"type":22},{"name":40,"class":41},""]